Download - Advances in Clinical Neuroscience and Rehabilitation

Editorial board and contributorsRoger Barker is co-editor of ACNR, and is Honorary Consultant inNeurology at The Cambridge Centre for Brain Repair. His main area ofresearch is into neurodegenerative and movement disorders, in particularparkinson's and Huntington's disease. He is also the university lecturer inNeurology at Cambridge where he continues to develop his clinical researchinto these diseases along with his basic research into brain repair usingneural transplants.Alasdair Coles is co-editor of ACNR. He is a University Lecturer inNeuroimmuniology at Cambridge University. He works on experimentalimmunological therapies in multiple sclerosis.Mike Zandi is co-editor of ACNR and Specialist Registrar in Neurology atAddenbrooke's Hospital, Cambridge. He trained in Cambridge, Norwich andLondon. He is interested in clinical and experimental neuroimmunology.Stephen Kirker is the editor of the Rehabilitation Section of ACNR andConsultant in Rehabilitation Medicine in Addenbrooke's NHS Trust,Cambridge. He trained in neurology in Dublin, London and Edinburghbefore moving to rehabilitation in Cambridge and Norwich. His mainresearch has been into postural responses after stroke. His particular interestsare in prosthetics, orthotics, gait training and neurorehabilitation.Boyd Ghosh is the Editor of our Conference News section. He is currentlya Specialist Registrar in Southampton having completed a PhD in Cambridgein cognitive neuroscience. His special interests are cognition and movementdisorders, with a particular interest in progressive supranuclear palsy.Rhys Davies is the editor of our Book Review Section. He is a consultantneurologist at the Walton Centre for Neurology and Neurosurgery inLiverpool and at Ysbyty Gwynedd in Bangor, North Wales. He has a clinicaland research interest in cognitive neurology.Alastair Wilkins is our Case Report Co-ordinator. He is Senior Lecturer inNeurology and Consultant Neurologist, University of Bristol. He trained inNeurology in Cambridge, Norwich and London. His research interests arethe basic science of axon degeneration and developing treatments forprogressive multiple sclerosis.Peter Whitfield is ACNR’s Neurosurgery Editor. He is a ConsultantNeurosurgeon at the South West Neurosurgery Centre, Plymouth. His clinicalinterests are wide including neurovascular conditions, head injury,stereotactic radiosurgery, image guided tumour surgery and lumbarmicrodiscectomy. He is an examiner for the MRCS and is a member of theSAC in neurosurgery.Heather Angus-Leppan is ACNR's ABN representative on the EditorialBoard. She is Head of the Neurology Department at Barnet Hospital andConsultant Neurologist, Honorary Senior Lecturer and Epilepsy Lead at theRoyal Free Hospital, London, UK. She is the Honorary Assistant Secretary ofthe Association of British Neurologists, Honorary Secretary of theNeurosciences Section of the Royal Society of Medicine and current Chairof the Map of Medicine Epilepsy Group, UK.International editorial liaison committeeProfessor Riccardo Soffietti, Italy: Chairman of the Neuro-Oncology Service, Dept ofNeuroscience and Oncology, University and S. Giovanni Battista Hospital.Professor Klaus Berek, Austria: Head of the Neurological Department of the KH Kufstein.Professor Hermann Stefan, Germany: Professor of Neurology /Epileptology in theDepartment of Neurology, University Erlangen-Nürnberg.Professor Nils Erik Gilhus, Norway: Professor of Neurology at the University of Bergen andHaukeland University Hospital.Episenta ® (sodium valproate)Prescribers should consult the Summary of Product Characteristics before prescribing Episenta ®Sodium valproate available as Episenta ® 150 or 300mg Prolonged-release Capsules, Episenta ®Sachets containing 500mg or 1000mg Prolonged-release Granules and Episenta ® 100mg/mlSolution for Injection. Indication: Epilepsy. Solution for injection: For use in patients normallymaintained on oral sodium valproate but temporarily not possible. Oral: For treatment of manicepisode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation oftreatment after manic episode could be considered in patients who have responded tovalproate for acute mania. Dose and Administration: Epilepsy: Oral: Monotherapy: Adults:600mg daily increasing by 150-300mg at 3-day intervals until controlled; usual dose range1000mg to 2000mg/day. Max dose 2500mg/day. Children >20kg: 300mg/day increasing untilcontrolled; usual dose range 20-30mg/kg/day. Max dose 35mg/kg/day. Children